Patents Assigned to Active Biotech AB
  • Publication number: 20200129499
    Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 30, 2020
    Applicant: ACTIVE BIOTECH AB
    Inventors: Jose Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
  • Patent number: 10385069
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder, an autoimmunity disorder or a neurodegenerative disorder.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: August 20, 2019
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, Stephen East, Marie Bainbridge, Colin MacKinnon, James Carr, Jonathan Hargrave
  • Patent number: 10314836
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: June 11, 2019
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • Patent number: 10300053
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: May 28, 2019
    Assignee: ACTIVE BIOTECH AB
    Inventors: Helena Eriksson, Leif Svensson, Marie Törngren
  • Patent number: 10125125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 13, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • Patent number: 9956212
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 1, 2018
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • Patent number: 9873687
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: January 23, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • Publication number: 20170319568
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 9, 2017
    Applicant: Active Biotech AB
    Inventors: Helena ERIKSSON, Leif SVENSSON, Marie TÖRNGREN
  • Patent number: 9771372
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 26, 2017
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, David Liberg, Maria Ekblad, Marie Bainbridge, Stephen East, Jonathan Hargrave, Natacha Prevost
  • Patent number: 9216956
    Abstract: Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl) -phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g. for the treatment of a malignant hyperproliferative disorder or an autoimmune disease.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: December 22, 2015
    Assignee: ACTIVE BIOTECH AB
    Inventor: Leif Svensson
  • Patent number: 8871936
    Abstract: A method for preparing a compound of formula (I) by reacting the appropriate alkyl ester and an aniline derivative, in a refluxing mixture containing an aliphatic solvent or a mixture of aliphatic solvents having a boiling point in the range of 68-191° C.; condensing vapors of the refluxing mixture; treating the condensed vapors with an alcohol scavenging agent or a mixture of alcohol scavenging agents; and returning the condensed vapors back to the reaction mixture.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: October 28, 2014
    Assignee: Active Biotech AB
    Inventors: Lillemor Maria Bock, Par Henning Holmberg, Karl-Erik Jansson
  • Patent number: 8841421
    Abstract: A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising:—determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or—determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: September 23, 2014
    Assignee: Active Biotech, AB
    Inventors: Per Bjork, Frederik Ivars, Tomas Leanderson
  • Patent number: 8754104
    Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: June 17, 2014
    Assignee: Active Biotech AB
    Inventors: Karl Jansson, Tomas Fristedt, Hans Wannman, Anders Bjork
  • Publication number: 20140112946
    Abstract: Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g. for the treatment of a malignant hyperproliferative disorder or an autoimmune disease.
    Type: Application
    Filed: June 22, 2012
    Publication date: April 24, 2014
    Applicant: ACTIVE BIOTECH AB
    Inventor: Leif Svensson
  • Patent number: 8545885
    Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 1, 2013
    Assignees: Teva Pharmaceutical Industries, Ltd., Active Biotech, AB
    Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
  • Publication number: 20130123301
    Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; to said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
    Type: Application
    Filed: November 6, 2012
    Publication date: May 16, 2013
    Applicant: ACTIVE BIOTECH AB
    Inventor: Active Biotech AB
  • Publication number: 20130109860
    Abstract: A method for preparing a compound of formula (I) by reacting the appropriate alkyl ester and an aniline derivative, in a refluxing mixture containing an aliphatic solvent or a mixture of aliphatic solvents having a boiling point in the range of 68-191° C.; condensing vapors of the refluxing mixture; treating the condensed vapors with an alcohol scavenging agent or a mixture of alcohol scavenging agents; and returning the condensed vapors back to the reaction mixture.
    Type: Application
    Filed: July 7, 2011
    Publication date: May 2, 2013
    Applicant: ACTIVE BIOTECH AB
    Inventors: Lillemor Maria Bock, Par Henning Holmberg, Karl-Erik Jansson
  • Patent number: 8314124
    Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: November 20, 2012
    Assignee: Active Biotech AB
    Inventors: Karl Jansson, Tomas Fristedt, Hans Wännman, Anders Björk
  • Patent number: 8293243
    Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: October 23, 2012
    Assignee: Active Biotech AB
    Inventors: Gunnar Hedlund, Göran Forsberg, Marie Wallén-öhman
  • Patent number: 7763253
    Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: July 27, 2010
    Assignee: Active Biotech, AB
    Inventors: Gunnar Hedlund, Göran Forsberg, Marie Wallén-öhman